Expert Recommendations for Prompt, Accurate Diagnosis and Effective Management of Low-Grade Serous Ovarian Carcinoma
CE Information
0.5 CE credits (0.12 pharmacology)Completion Time
30 minutesAvailable Until
June 15, 2024Posted By
Prime CE
Navigate
Overview
Specialties
Acute Care and Women's HealthSubspecialties
OncologyClinical Topics
OncologyIntended Audience: Medical oncologists and their clinical teams, including NPs, PAs, nurses, and pharmacists
Low-grade serous ovarian carcinoma (LGSOC) is a rare form of ovarian cancer with few treatment options. Accurate diagnosis of LGSOC, and its differentiation from high-grade serous ovarian carcinoma, plays a key role in selecting appropriate treatment strategies for this condition.
Join us for part 1 of our three-part series for expert discussion on identifying LGSOC through histological and molecular characteristics, and guideline recommendations for the management of LGSOC.
Learning Objectives
- Review histopathological, immunohistochemical, and molecular characteristics that contribute to a prompt, accurate diagnosis of low-grade serous ovarian carcinoma (LGSOC) and differentiate it from high-grade serous ovarian carcinoma (HGSC) and endometrial cancer
- Apply current guideline recommendations to LGSOC management, including diagnosis and treatment selection in the primary and recurrent disease settings
Speakers
Associate Professor, Section of Gynecologic Oncology
Jim and Christy Everest Endowed Chair in Cancer Research
Director, Oklahoma TSET Phase I Program
OU Stephenson Cancer Center
Oklahoma University College of Medicine
Oklahoma City, OK
Kathleen N Moore, MD, is an Associate Professor in the Section of Gynecologic Oncology; the Jim and Christy Everest Endowed Chair in Cancer Research; and the Director of the Oklahoma TSET Phase I Program for the Stephenson Cancer Center at the University of Oklahoma College of Medicine. She attended medical school at the University of Washington School of Medicine and completed her residency in obstetrics and gynecology at the University Health Center of Pittsburgh. Dr Moore completed a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center while simultaneously earning a master's degree in epidemiology. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. She serves as the Associate Director of Clinical Research and Medical Director of the Clinical Trials Office for the Stephenson Cancer Center. She has published over 200 peer-reviewed publications and serves on the editorial board for four academic publications. She has a clinical research interest in drug development and phase I trials.
Professor, Department of Obstetrics and Gynecology
Director, Division of Gynecologic Oncology
Director, Clinical Research
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University College of Medicine
Columbus, OH
David M O'Malley, MD, is a Professor and Director of the Division of Gynecologic Oncology at The Ohio State University College of Medicine in Columbus, Ohio. Dr O'Malley attended medical school at Wayne State and earned his undergraduate degree at the University of Notre Dame. He completed his fellowship in gynecologic oncology at Yale University. He completed his residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation. Dr O'Malley serves as the ORIEN physician liaison for The Ohio State University Comprehensive Cancer Center. He is an active committee member for the NCI Gynecologic Cancer Steering Committee's Ovarian Task Force, NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), the Society of Gynecologist Oncology (SGO), and the American Society of Clinical Oncology (ASCO). He was appointed to the panel of the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer where he continues to be an active participant. As a member of the Translational Therapeutics Program, his research is focused on identifying novel and innovative therapies for gynecologic cancers. He has designed, coordinated, and published on all levels of clinical trials to include phase I, II, and III studies with a special interest in novel compounds. Dr O'Malley has authored over 100 publications in journals such as the New England Journal of Medicine, the Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology, and Nature Genetics.
CE Information
This activity offers 0.5 CE credits (0.12 pharmacology) to attendees.
Nurse Practitioner Accreditation Statement
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.12 hour of pharmacology).
Disclosures
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
-
Kathleen N Moore, MD (Speaker)
Advisory Board or Panel – Aadi, Alkemeres, Aravive, AstraZeneca, Blueprint Pharma, Caris, Clovis, Eisai, Genentech/Roche, GlaxoSmithKline/Tesaro, Hengrui, Immunogen, Janssen, Merck, Mersana, Myriad, Novartis, OncXerna, Tarveda, Teneo Bio, VBL Therapeutics, VerastemThe relationships reported above are related to the following therapeutic area: Oncology
Consultant – AstraZeneca
Grants / Research Support – Lilly -
David M O'Malley, MD (Speaker)
Advisory Board or Panel – Agenus, Ambry Genetics, AstraZeneca, Clovis, Eisai, Elevar, GOG Foundation, Genelux, Genentech, GlaxoSmithKline, Immunogen, Iovance, Janssen, LEAP Therapeutics, Merck, Mersana, Myriad, Novartis, Novocure, Regeneron, Roche Diagnostics MSA, Rubis, Seattle Genetics, Sorrento, Tarveda Therapeutics, Tesaro
Consultant – AbbVie, Agenus, Eisai, GOG Foundation, Genentech, Immunogen, Novocure, Seattle Genetics
Grants / Research Support – AMGEN, AbbVie, Agenus, Ajinomoto Inc, Array Biopharma, AstraZeneca, Clovis, EMD Serono, Eisai, GOG Foundation, Genentech, GlaxoSmithKline, Immunogen, Iovance, Janssen, LEAP Therapeutics, Merck, Mersana, Novocure, Regeneron, Seattle Genetics, Tesaro
The following individuals have no relevant financial relationships with ineligible companies to disclose:
- Lisa Wakefield, MSN, APRN, FNP-BC (Reviewer)
- Abimbola Farinde, PhD, PharmD (Planner)
- Stephanie Joyce, PA, MSPAS, MS, RD CNSC (Planner)
All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity